Literature DB >> 11090880

Genes coding evolutionary novel anti-carbohydrate antibodies: studies on anti-Gal production in alpha 1,3galactosyltransferase knock out mice.

Z C Chen1, M Z Radic, U Galili.   

Abstract

This study analyzes the gene repertoire coding for antibodies to an evolutionary novel immunogenic carbohydrate antigen in mice. The alpha-gal epitope (Gal alpha 1-3Gal beta 1-4GlcNAc-R) is an autoantigen, abundantly expressed in wild type mice, but absent in alpha 1,3galactosyltransferase knock-out (KO) mice, where it can induce the production of the anti-Gal antibody. Hybridoma clones secreting anti-Gal were isolated from different mice and their immunoglobulin genes were analyzed. All anti-Gal clones were found to be encoded by the heavy chain gene VH22.1 and light chain gene VK5.1. Moreover, one 'forbidden' anti-Gal clone, produced in a wild type mouse, was also encoded by VH 22.1 and VK 5.1. The genes coding for the different anti-Gal clones were found to contain somatic mutations and different CDR3 domains. These data imply that a highly restricted gene usage combined with junctional diversity and somatic mutations can generate new antibodies that have not been produced in the course of the evolution of a species.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11090880     DOI: 10.1016/s0161-5890(00)00064-x

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  7 in total

1.  Genetic and structural basis of the human anti-α-galactosyl antibody response.

Authors:  David B Langley; Peter Schofield; Damien Nevoltris; Jennifer Jackson; Katherine J L Jackson; Tim J Peters; Melanie Burk; Jacqueline M Matthews; Antony Basten; Christopher C Goodnow; Sheryl van Nunen; Joanne H Reed; Daniel Christ
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-08       Impact factor: 12.779

2.  Tolerance to self gangliosides is the major factor restricting the antibody response to lipopolysaccharide core oligosaccharides in Campylobacter jejuni strains associated with Guillain-Barré syndrome.

Authors:  Tyrone Bowes; Eric R Wagner; Judith Boffey; Dawn Nicholl; Lynne Cochrane; Mustapha Benboubetra; Joe Conner; Keiko Furukawa; Koichi Furukawa; Hugh J Willison
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

3.  Defining the recognition elements of Lewis Y-reactive antibodies.

Authors:  Somdutta Saha; Anastas Pashov; Eric R Siegel; Ramachandran Murali; Thomas Kieber-Emmons
Journal:  PLoS One       Date:  2014-08-12       Impact factor: 3.240

4.  Alpha-Gal and Cross-Reactive Carbohydrate Determinants in the N-Glycans of Salivary Glands in the Lone Star Tick, Amblyomma americanum.

Authors:  Yoonseong Park; Donghun Kim; Gunavanthi D Boorgula; Kristof De Schutter; Guy Smagghe; Ladislav Šimo; Stephanie A Archer-Hartmann; Parastoo Azadi
Journal:  Vaccines (Basel)       Date:  2020-01-09

5.  A novel monoclonal IgG1 antibody specific for Galactose-alpha-1,3-galactose questions alpha-Gal epitope expression by bacteria.

Authors:  Luisa Kreft; Aloys Schepers; Miriam Hils; Kyra Swiontek; Andrew Flatley; Robert Janowski; Mohammadali Khan Mirzaei; Michael Dittmar; Neera Chakrapani; Mahesh S Desai; Stefanie Eyerich; Li Deng; Dierk Niessing; Konrad Fischer; Regina Feederle; Simon Blank; Carsten B Schmidt-Weber; Christiane Hilger; Tilo Biedermann; Caspar Ohnmacht
Journal:  Front Immunol       Date:  2022-08-05       Impact factor: 8.786

6.  Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data.

Authors:  Ana M Vázquez; Ana M Hernández; Amparo Macías; Enrique Montero; Daniel E Gómez; Daniel F Alonso; Mariano R Gabri; Roberto E Gómez
Journal:  Front Oncol       Date:  2012-10-23       Impact factor: 6.244

7.  Proteomic analysis of tissue from α1,3-galactosyltransferase knockout mice reveals that a wide variety of proteins and protein fragments change expression level.

Authors:  Louise Thorlacius-Ussing; Maja Ludvigsen; Svend Kirkeby; Henrik Vorum; Bent Honoré
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.